Last updated on June 2015

Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive Morbidly Obese Patients With Pneumonia


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pneumonia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    BMI >35
    Radiographically and clinically documented pneumonia and one of the following:
    the patient is MRSA screen-positive and is as such at high risk for MRSA
    pneumonia (MIC for linezolid is known or possible to assess)
    the patient has a baseline respiratory tract sample positive for MRSA; MRSA
    pneumonia is likely
    empiric therapy without linezolid is initiated (no obvious indication for MRSA
    involvement), but the patient is switch to linezolid therapy once culture
    results demonstrate MRSA as pathogen. CAVE: the patients must be included in the
    tudy prior to the moment the first trough sample must be drawn. As such,
    patients becoming MRSA-positive after >1 dose of linezolid cannot be included in
    the study.
    Decision to start treatment with linezolid for at least 3 days (6 doses of 600 mg).
    Patient is colonized or infected with MRSA (at any site) and it must be possible to
    ent a fresh isolate to the central laboratory for microbiology.
    Written informed consent by the patient or his/her legal representative.

You may not be eligible for this study if the following are true:

  • Contraindications as described in the summary of product characteristics (SPC).

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.